Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Beam Therapeutics Q3 EPS $(1.10) Misses $(1.05) Estimate, Sales $9.698M Miss $12.368M Estimate

Author: Benzinga Newsdesk | November 04, 2025 07:09am
Beam Therapeutics (NASDAQ:BEAM) reported quarterly losses of $(1.10) per share which missed the analyst consensus estimate of $(1.05) by 5.16 percent. This is a 5.98 percent increase over losses of $(1.17) per share from the same period last year. The company reported quarterly sales of $9.698 million which missed the analyst consensus estimate of $12.368 million by 21.59 percent. This is a 32.03 percent decrease over sales of $14.269 million the same period last year.

Posted In: BEAM


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist